BioStock: Lipum's CEO comments on the positive study results

Umeå-based Lipum has successfully completed the first part of the clinical phase I study where the drug candidate SOL-116 is tested in healthy subjects. The results confirm that SOL-116 continues to have a good safety profile and desirable pharmacokinetic profile. The candidate interacts with its target protein BSSL and reduces the levels of BSSL in blood plasma. Lipum's CEO Ola Sandborgh tells us more about the results in an interview.  

Read the full article at biostock.se:

https://www.biostock.se/en/2024/02/lipums-ceo-comments-on-the-positive-study-results/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se